11 completed, 3 terminated. 14 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 14 | Completed 11, Terminated 3 |
| Phase 2 | 2 | Completed 2 |
Follow fremanezumab: new trials by email Literature Review of fremanezumab trials Research Report on fremanezumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 365 | 2022-09-30 | 2025-11-26 |
| A Study to Test if Fremanezumab is Effective in Preventing Chronic Migraine in Participants 6 to 17 Years of Age Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 292 | 2020-09-24 | 2025-12-19 |
| A Trial to Test if Fremanezumab is Effective in Preventing Migraine in Children and Adolescents Fremanezumab - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D LLC | 499 | 2020-09-16 | 2026-07-24 |
| A Study to Test if Fremanezumab is Effective in Preventing Episodic Migraine in Patients 6 to 17 Years of Age Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 235 | 2020-07-15 | 2026-06-22 |
| Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine TEV-48125, TEV-48125 or placebo, Placebo - Migraine | Phase 2 / Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 357 | 2017-12-19 | 2021-07-29 |
| Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine TEV-48125, TEV-48125 or placebo, Placebo - Migraine | Phase 2 / Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 571 | 2017-12-19 | 2021-06-15 |
| Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine TEV-48125 - Migraine | Phase 3 | Completed | Otsuka Pharmaceutical Co., Ltd. | 50 | 2017-12-07 | 2023-02-17 |
| An Efficacy and Safety Study of Fremanezumab in Adults With Migraine Fremanezumab, Placebo - Migraine Prophylaxis | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 838 | 2017-10-13 | 2021-11-09 |
| A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache Fremanezumab - Cluster Headache | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 275 | 2017-04-27 | 2021-11-09 |
| A Study to Evaluate the Efficacy and Safety of TEV-48125 (Fremanezumab) for the Prevention of Episodic Cluster Headache (ECH) Fremanezumab, Placebo - Episodic Cluster Headache | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 169 | 2017-01-19 | 2021-11-09 |
| A Study Comparing the Efficacy and Safety of Fremanezumab (TEV-48125) for the Prevention of Chronic Cluster Headache (CCH) Fremanezumab, Placebo - Chronic Cluster Headache | Phase 3 | Terminated | Teva Branded Pharmaceutical Products R&D, Inc. | 259 | 2017-01-17 | 2021-11-09 |
| Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 875 | 2016-03-23 | 2021-11-09 |
| Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1130 | 2016-03-22 | 2021-11-09 |
| Efficacy and Safety of Subcutaneous Administration of Fremanezumab (TEV-48125) for the Preventive Treatment of Migraine Fremanezumab, Placebo - Migraine | Phase 3 | Completed | Teva Branded Pharmaceutical Products R&D, Inc. | 1890 | 2016-02-26 | 2021-11-09 |
Migraine Disorders (10) · Cluster Headache (3)
Teva Branded Pharmaceutical Products R&D, Inc. (10) · Otsuka Pharmaceutical Co., Ltd. (3) · Teva Branded Pharmaceutical Products R&D LLC (1)
Finland (10) · Poland (10) · Spain (10) · United States (10) · Canada (9) · Israel (9) · Germany (7) · Italy (7) · Netherlands (7) · Japan (6) · Czechia (4) · Sweden (4) · United Kingdom (4) · Australia (3) · Russia (3)
PMID 34819017, PMID 35331009, PMID 36038833, PMID 33413075, PMID 35139816, PMID 39221611, PMID 29171818, PMID 29800211, PMID 31427046, PMID 31675102, PMID 31752521, PMID 32747522, PMID 32887548, PMID 32913018, PMID 32958075, PMID 33863272, PMID 33990144, PMID 34246226, PMID 34687446, PMID 34922436, PMID 35302681, PMID 41534042, PMID 42616035
2015 (3), 2016 (3), 2019 (3), 2017 (1)